Bitter melon polypeptide fermentation microgranule structure

Abstract

A bitter melon polypeptide fermented microgranule structure is provided. The microparticle structure comprises a microparticle body 10, which is round and spherical and contains a natto fermentation product 11 and a bitter melon extract 12. The microparticle body is produced by fermenting the natto fermentation product with the bitter melon extract in a ratio of 1:1 to 1:4. This improves biocompatibility, reduces irritation to the human body, and promotes the uniform release of health benefits, thereby improving therapeutic effects and reducing side effects, and is particularly useful for health management for diabetics and people at risk of hyperglycemia.

Description

[Technical Field]

[0001] The present invention relates to a microgranule structure, especially to a bitter melon polypeptide fermented microgranule structure suitable for health care products for diabetes and related metabolic diseases. [Background technology]

[0002] Diabetes is a chronic metabolic disease characterized by impaired glucose metabolism due to insulin deficiency or impaired tissue response to insulin, ultimately resulting in hyperglycemia. When blood glucose levels rise and exceed the renal absorption limit, glucose is excreted in the urine, resulting in glycosuria. Diabetes is divided into Type 1 and Type 2 diabetes depending on the cause. Type 1 diabetes patients' pancreas is unable to secrete insulin, making them insulin-dependent. Type 2 diabetes patients are classified as non-insulin-dependent due to insulin intolerance or insufficient insulin secretion. Both Type 1 and Type 2 diabetes patients experience symptoms of hyperglycemia. Research has shown that approximately 80% of Type 2 diabetes patients also experience obesity.

[0003] The key to improving type 2 diabetes is for patients to keep blood sugar stable and balanced, lose weight, avoid sweet foods, sugary drinks, alcohol and high-sugar fruits, and exercise regularly. In addition, patients may also consider taking healthy nutritional supplements that can help lower blood sugar.

[0004] Research has shown that bitter melon extract has various effects such as antioxidant, hypotensive, hypolipidemic, hypoglycemic, and metabolic promotion, among which the hypoglycemic effect is particularly prominent. Therefore, further exploration of active ingredients with significant therapeutic effects on diabetes is expected to be widely pursued, and will help to effectively improve people's health problems. Summary of the Invention [Problem to be solved by the invention]

[0005] In light of the above issues we are trying to solve, we came up with this idea, and after much discussion, prototyping, and making many modifications and improvements, we are now proposing this idea. [Means for solving the problem]

[0006] The bitter melon polypeptide fermented microparticle structure of the present invention comprises a microparticle body, which is round and spherical, contains a natto fermentation product and a bitter melon extract, and is produced by fermenting the natto fermentation product with the bitter melon extract in a ratio of 1:1 to 1:4.

[0007] In one embodiment of the present invention, the bitter melon polypeptide fermented microparticle structure further comprises a protective layer, which covers the outside of the microparticle body, thereby preventing external environmental factors from affecting the activity of the microparticle body, and thereby improving the storage stability and human absorption rate of the microparticle body. [Effects of the Invention]

[0008] The bitter melon polypeptide fermented microparticle structure of this invention has a round spherical microparticle body, which is more biocompatible, thereby reducing irritation to the human body and promoting the uniform release of health benefits. This helps to improve the therapeutic effect, reduce side effects, increase the solubility of drugs and promote their absorption, and is mainly intended to help diabetics and people at risk of hyperglycemia, improve blood sugar, and promote and control metabolism, thereby achieving health management effects. [Brief explanation of the drawings]

[0009] [Figure 1] FIG. 1 is a three-dimensional cross-sectional view of the present invention. [Figure 2] FIG. 2 is a plan cross-sectional view of the present invention. [Figure 3] FIG. 3 is a schematic diagram of the glial sac filling of the present invention. Forms for implementing a utility model

[0010] We will now further describe the present invention in conjunction with the drawings of preferred embodiments of the present invention so that those skilled in the art can implement the present invention according to the description herein.

[0011] As shown in FIGS. 1 and 2, the bitter melon polypeptide fermentation microparticle structure according to the present invention comprises a microparticle body 10 and a protective layer 20 .

[0012] The microparticle body 10 is formed into a round sphere and contains a natto fermentation product 11 and a bitter melon extract 12. The microparticle body 10 is produced by fermenting the natto fermentation product 11 with the bitter melon extract 12 in a ratio of 1:1 to 1:4. The microparticle body 10 is homogeneous, thereby ensuring the efficacy and stability of the product. The microparticle structure 10 not only preserves the nutrients of bitter melon, but also enhances its biological activity through the natto fermentation process, thereby improving the blood sugar control effect. The ratio of 1:1 to 1:4 refers to the ratio of the mass of the natto fermentation product 11 to the mass of the bitter melon extract 12. These ingredients interact with each other through a scientific fermentation process, helping to regulate blood sugar levels and improve insulin sensitivity.

[0013] The protective layer 20 covers the outside of the microparticles 10, thereby preventing external environmental factors from affecting the activity of the microparticles 10, and therefore improving the storage stability and human absorption rate of the microparticles 10. The protective layer 20 prevents the active ingredients in the microparticles 10 from being lost during storage and use. The design of the protective layer 20 takes into account the release characteristics of the microparticles 10, ensuring that the active ingredients are gradually released into the human body and enhancing bioavailability, which allows the nutritional ingredients in the microparticles 10 to be better absorbed in the digestive tract and therefore improves the blood sugar control effect.

[0014] When taking the bitter melon polypeptide fermented granules, it is possible to take them orally, or as shown in Figure 3, fill a predetermined amount of the bitter melon polypeptide fermented granules into a gelatinous sac 30 and swallow the gelatinous sac 30.

[0015] With the development of science and technology, the application prospects of bitter melon polypeptide fermented granules will be expanded. It is expected that this product will not only be suitable for the daily health care of diabetic patients, but also be put on the market as a health food, meeting consumer demand for natural and effective health food. In addition, in combination with modern nutrition and food science, more comprehensive health products can be developed based on bitter melon polypeptide fermented granules in the future.

[0016] To verify the effectiveness of this invention, we conducted experiments on the expression of genes related to glucose uptake. Figure 1 shows the expression levels of genes related to glucose uptake under different conditions. The vertical axis shows the ratio of gene expression to GAPDH (GAPDH / gene expression), and the horizontal axis shows the different experimental groups.

[0017] The normal experimental group represents the normal or untreated condition.

[0018] The experimental group called bitter melon represents the processed state of bitter melon.

[0019] The experimental group of bitter melon natto represents the processed state of the bitter melon polypeptide fermented granules according to the present invention.

[0020] Figure 1 shows genes represented by histograms of different colors. (Chart 1) JPEG0003252509000002.jpg101159TIFF0003252509000003.tif31127

[0021] From Figure 1, it can be seen that the administration of bitter melon polypeptide fermented granules of the present invention has a positive regulatory effect on the gene expression of multiple glucose transport proteins, especially SLC2A2, SLC2A10, and SLC5A3. These multiple glucose transport proteins play an important role in glucose transport in various tissues and cells in the human body. These results indicate that the bitter melon polypeptide fermented granules of the present invention have a certain effect on glucose metabolism.

[0022] Furthermore, we test the expression of genes related to insulin induction. As shown in Figure 2, the expression levels of insulin-related genes under different conditions are shown. The vertical axis shows the ratio of gene expression to GAPDH (GAPDH / gene expression), and the horizontal axis represents different experimental groups.

[0023] NC (negative control) represents the normal or untreated condition.

[0024] The experimental group called bitter melon represents the processed state of bitter melon.

[0025] The experimental group of bitter melon natto represents the processed state of the bitter melon polypeptide fermented granules according to the present invention.

[0026] Figure 2 shows the genes represented by histograms of different colors. (Chart 2) JPEG0003252509000004.jpg92134TIFF0003252509000005.tif39124

[0027] From Figure 2, it can be seen that the administration of the bitter melon polypeptide fermented granules of the present invention can significantly increase the expression level of the INSIG2 gene. The treatment of the bitter melon polypeptide fermented granules of the present invention has a relatively small effect on the expression levels of the other detected insulin-related genes.

[0028] Due to the structure of the above specific embodiment, the following beneficial effects may be obtained.

[0029] The bitter melon polypeptide fermented microparticle structure of the present invention has a round spherical microparticle body 10, which makes it more biocompatible, thereby reducing irritation to the human body, and its distribution is more uniform, which accelerates the release of health benefits, thereby improving the therapeutic effect and reducing side effects. The fermentation and microparticle processing greatly increases the solubility in water, which promotes intestinal absorption, helping diabetics and people at risk of hyperglycemia, improving blood sugar and promoting and regulating metabolism, thereby achieving health management effects, and therefore has the potential to be widely used in the health field. [Explanation of symbols]

[0030] 10- Fine grain body; 11- Bacillus natto fermented product; 12- Bitter melon extract; 20- Protective layer; 30- Glue sac

Claims

1. The fine particle body has a round spherical shape and contains a natto fermentation product and a bitter melon extract. The natto fermentation product is fermented with the bitter melon extract in a ratio of 1:1 to 1:

4. A bitter melon polypeptide fermented microgranule structure characterized by:

2. The present invention further comprises a protective layer, which covers the outside of the particulate body, thereby preventing external environmental factors from affecting the activity of the particulate body, thereby improving the storage stability and human absorption rate of the particulate body. The bitter melon polypeptide fermented microgranule structure according to claim 1.

3. The bitter melon polypeptide fermented microgranule structure according to claim 1, characterized in that the microgranule body is in a homogeneous state.

Images